Charles Zhu
Stock Analyst
(n/a)
# 4,648
Out of 4,648 analysts
22
Total ratings
n/a
Success rate
n/a
Average return
Main Sectors:
Top Industries:
Stocks Rated by Charles Zhu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TNGX Tango Therapeutics | Maintains: Buy | $16 → $14 | $5.16 | +171.32% | 2 | May 24, 2024 | |
| MGNX MacroGenics | Upgrades: Buy | $12 | $3.70 | +224.32% | 4 | Nov 7, 2023 | |
| MRUS Merus | Maintains: Buy | $46 → $48 | $51.23 | -6.30% | 6 | Aug 8, 2023 | |
| NUVL Nuvalent | Initiates: Buy | $56 | $89.53 | -37.45% | 1 | Jul 24, 2023 | |
| TARA Protara Therapeutics | Assumes: Buy | $22 | $2.59 | +749.42% | 1 | Jul 10, 2023 | |
| COGT Cogent Biosciences | Reiterates: Buy | $26 | $11.87 | +119.04% | 3 | Jun 13, 2023 | |
| IDYA IDEAYA Biosciences | Reiterates: Buy | $32 | $30.00 | +6.67% | 3 | Mar 8, 2023 | |
| ZYME Zymeworks | Upgrades: Buy | $14 | $14.76 | -5.15% | 2 | May 5, 2022 |
Tango Therapeutics
May 24, 2024
Maintains: Buy
Price Target: $16 → $14
Current: $5.16
Upside: +171.32%
MacroGenics
Nov 7, 2023
Upgrades: Buy
Price Target: $12
Current: $3.70
Upside: +224.32%
Merus
Aug 8, 2023
Maintains: Buy
Price Target: $46 → $48
Current: $51.23
Upside: -6.30%
Nuvalent
Jul 24, 2023
Initiates: Buy
Price Target: $56
Current: $89.53
Upside: -37.45%
Protara Therapeutics
Jul 10, 2023
Assumes: Buy
Price Target: $22
Current: $2.59
Upside: +749.42%
Cogent Biosciences
Jun 13, 2023
Reiterates: Buy
Price Target: $26
Current: $11.87
Upside: +119.04%
IDEAYA Biosciences
Mar 8, 2023
Reiterates: Buy
Price Target: $32
Current: $30.00
Upside: +6.67%
Zymeworks
May 5, 2022
Upgrades: Buy
Price Target: $14
Current: $14.76
Upside: -5.15%